PT  - JOURNAL ARTICLE
AU  - Topf, Katherine G
AU  - Sheppard, Michael
AU  - Marx, Grace E.
AU  - Wiegand, Ryan E
AU  - Link-Gelles, Ruth
AU  - Binder, Alison M
AU  - Cool, Andrea J
AU  - Lyons, B. Casey
AU  - Park, Sohyun
AU  - Fast, Hannah E
AU  - Presnetsov, Arthur
AU  - Azondekon, G Roseric
AU  - Soetebier, Karl A
AU  - Adjemian, Jennifer
AU  - Barbour, Kamil E
TI  - Impact of the COVID-19 Vaccination Program on Case Incidence, Emergency Department Visits, and Hospital Admissions among Children Aged 5–17 Years during the Delta and Omicron Periods —United States, December 2020 to April 2022
AID  - 10.1101/2022.10.07.22280822
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.07.22280822
4099  - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280822.short
4100  - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280822.full
AB  - Background In the United States, national ecological studies suggest a positive impact of COVID-19 vaccination coverage on outcomes in adults. However, the national impact of the vaccination program on COVID-19 in children remains unknown. To determine the association of COVID-19 vaccination with U.S. case incidence, emergency department visits, and hospital admissions for pediatric populations during the Delta and Omicron periods.Methods We conducted an ecological analysis among children aged 5–17 and compared incidence rate ratios (RRs) of COVID-19 cases, emergency department visits, and hospital admissions by pediatric vaccine coverage, with jurisdictions in the highest vaccine coverage quartile as the reference.Results RRs comparing states with lowest pediatric vaccination coverage to the highest pediatric vaccination coverage were 2.00 and 0.64 for cases, 2.96 and 1.11 for emergency department visits, and 2.76 and 1.01 for hospital admissions among all children during the Delta and Omicron periods, respectively. During the 3-week peak period of the Omicron wave, only children aged 12–15 and 16–17 years in the states with the lowest versus highest coverage, had a significantly higher rate of emergency department visits (RR=1.39 and RR=1.34, respectively).Conclusions COVID-19 vaccines were associated with lower case incidence, emergency department visits and hospital admissions among children during the Delta period but the association was weaker during the Omicron period. Pediatric COVID-19 vaccination should be promoted as part of a program to decrease COVID-19 impact among children; however, vaccine effectiveness may be limited when available vaccines do not match circulating viral variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the CDC’s regular operating funds. The CDC was involved in the study design, data analysis, data interpretations, and writing and submission of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by the Centers for Disease Control and Prevention's (CDC) Human Research Protection Office and determined to be exempt from human participants' research regulations, including the need for documented written consent, as the activities involved identification, control or prevention of disease in response to an immediate public health threat. It was conducted consistent with applicable federal law and CDC policyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.